Aspects of B-cell non-hodgkin's lymphoma development: A transition from immune-reactivity to malignancy

A. Illés, L. Varoczy, G. Papp, P. C. Wilson, P. Alex, R. Jonsson, T. Kovacs, Y. T. Konttinen, M. Zeher, B. Nakken, P. Szodoray

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The development of B-cell lymphomas is an intricate interplay among various pathogenic factors, leading to a multi-step process, encompassing various stages of B-cell maturation. Besides genetic abnormalities, a variety of environmental and microbial factors, as well as disproportional immune-regulatory processes lead to the malignant transformation. Yet, little is known about the exact chain of events, which lead from the physiological polyclonal B-cell activation as a response to exogenous antigens through oligoclonality to a monoclonal, uncontrolled, malignant B-cell proliferation. The aim of the present review was to summarize the potential harmful steps in the development of B-cell lymphomas, according to conventional and novel theories, and to depict therapeutic regimens presently in use as well as to envision future drug developments, beneficial in the battle against this lymphoid malignancy.

Original languageEnglish
Pages (from-to)387-400
Number of pages14
JournalScandinavian Journal of Immunology
Volume69
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
B-Lymphocytes
Neoplasms
Cell Proliferation
Antigens
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Aspects of B-cell non-hodgkin's lymphoma development : A transition from immune-reactivity to malignancy. / Illés, A.; Varoczy, L.; Papp, G.; Wilson, P. C.; Alex, P.; Jonsson, R.; Kovacs, T.; Konttinen, Y. T.; Zeher, M.; Nakken, B.; Szodoray, P.

In: Scandinavian Journal of Immunology, Vol. 69, No. 5, 05.2009, p. 387-400.

Research output: Contribution to journalArticle

Illés, A, Varoczy, L, Papp, G, Wilson, PC, Alex, P, Jonsson, R, Kovacs, T, Konttinen, YT, Zeher, M, Nakken, B & Szodoray, P 2009, 'Aspects of B-cell non-hodgkin's lymphoma development: A transition from immune-reactivity to malignancy', Scandinavian Journal of Immunology, vol. 69, no. 5, pp. 387-400. https://doi.org/10.1111/j.1365-3083.2009.02237.x
Illés, A. ; Varoczy, L. ; Papp, G. ; Wilson, P. C. ; Alex, P. ; Jonsson, R. ; Kovacs, T. ; Konttinen, Y. T. ; Zeher, M. ; Nakken, B. ; Szodoray, P. / Aspects of B-cell non-hodgkin's lymphoma development : A transition from immune-reactivity to malignancy. In: Scandinavian Journal of Immunology. 2009 ; Vol. 69, No. 5. pp. 387-400.
@article{2b95d378edeb4de794e6453b7e63cc43,
title = "Aspects of B-cell non-hodgkin's lymphoma development: A transition from immune-reactivity to malignancy",
abstract = "The development of B-cell lymphomas is an intricate interplay among various pathogenic factors, leading to a multi-step process, encompassing various stages of B-cell maturation. Besides genetic abnormalities, a variety of environmental and microbial factors, as well as disproportional immune-regulatory processes lead to the malignant transformation. Yet, little is known about the exact chain of events, which lead from the physiological polyclonal B-cell activation as a response to exogenous antigens through oligoclonality to a monoclonal, uncontrolled, malignant B-cell proliferation. The aim of the present review was to summarize the potential harmful steps in the development of B-cell lymphomas, according to conventional and novel theories, and to depict therapeutic regimens presently in use as well as to envision future drug developments, beneficial in the battle against this lymphoid malignancy.",
author = "A. Ill{\'e}s and L. Varoczy and G. Papp and Wilson, {P. C.} and P. Alex and R. Jonsson and T. Kovacs and Konttinen, {Y. T.} and M. Zeher and B. Nakken and P. Szodoray",
year = "2009",
month = "5",
doi = "10.1111/j.1365-3083.2009.02237.x",
language = "English",
volume = "69",
pages = "387--400",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Aspects of B-cell non-hodgkin's lymphoma development

T2 - A transition from immune-reactivity to malignancy

AU - Illés, A.

AU - Varoczy, L.

AU - Papp, G.

AU - Wilson, P. C.

AU - Alex, P.

AU - Jonsson, R.

AU - Kovacs, T.

AU - Konttinen, Y. T.

AU - Zeher, M.

AU - Nakken, B.

AU - Szodoray, P.

PY - 2009/5

Y1 - 2009/5

N2 - The development of B-cell lymphomas is an intricate interplay among various pathogenic factors, leading to a multi-step process, encompassing various stages of B-cell maturation. Besides genetic abnormalities, a variety of environmental and microbial factors, as well as disproportional immune-regulatory processes lead to the malignant transformation. Yet, little is known about the exact chain of events, which lead from the physiological polyclonal B-cell activation as a response to exogenous antigens through oligoclonality to a monoclonal, uncontrolled, malignant B-cell proliferation. The aim of the present review was to summarize the potential harmful steps in the development of B-cell lymphomas, according to conventional and novel theories, and to depict therapeutic regimens presently in use as well as to envision future drug developments, beneficial in the battle against this lymphoid malignancy.

AB - The development of B-cell lymphomas is an intricate interplay among various pathogenic factors, leading to a multi-step process, encompassing various stages of B-cell maturation. Besides genetic abnormalities, a variety of environmental and microbial factors, as well as disproportional immune-regulatory processes lead to the malignant transformation. Yet, little is known about the exact chain of events, which lead from the physiological polyclonal B-cell activation as a response to exogenous antigens through oligoclonality to a monoclonal, uncontrolled, malignant B-cell proliferation. The aim of the present review was to summarize the potential harmful steps in the development of B-cell lymphomas, according to conventional and novel theories, and to depict therapeutic regimens presently in use as well as to envision future drug developments, beneficial in the battle against this lymphoid malignancy.

UR - http://www.scopus.com/inward/record.url?scp=64549160703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64549160703&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3083.2009.02237.x

DO - 10.1111/j.1365-3083.2009.02237.x

M3 - Article

C2 - 19508370

AN - SCOPUS:64549160703

VL - 69

SP - 387

EP - 400

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 5

ER -